Important Announcements & Notices

Announcement:G&E's New Drug, SR-T100 Injection
has received a consultation response from CDE, and 
will formally apply to the TFDA for Phase I clinical trial.

1.Date of occurrence of the event:2026/03/31
2.Company name:G&E HERBAL BIOTECHNOLOGY CO., LTD.
3.Relationship to the Company (please enter ”head office” or
  ”subsidiaries”):The Company
4.Reciprocal shareholding ratios: Not applicable
5.Cause of occurrence:
G&E’s self-developed SR-T100 injection (indication:
treatment of malignant ascites in cancer patients),
has officially received the clinical trial consultation
response report from the Center for Drug Evaluation (CDE)
after consultation. G&E will, according to the
consultation opinion, prepare all relevant documents for
the clinical trial and then submit an application for
Phase I human clinical trial (IND) to the Taiwan Food
and Drug Administration (TFDA).
Malignant ascites is a severe complication commonly
seen in the treatment process or late stages of cancer,
especially in abdominal cancers such as ovarian, gastric,
colorectal, liver, and pancreatic cancer. Currently,
there are no approved and effective drugs for this
condition globally.Most clinical management involves
repeated paracentesis to temporarily relieve patient
suffering. Although there have been more than a dozen
international clinical trials for new drugs targeting
this indication,all have been discontinued due to serious
side effects or unsatisfactory efficacy. Therefore,there
is a significant unmet and urgent medical need in
clinical practice.
6.Countermeasures:None
7.Any other matters that need to be specified(the information
 disclosure also meets the requirements of Article 7, subparagraph 9
 of the Securities and Exchange Act Enforcement Rules, which brings
 forth a significant impact on shareholders rights or the price of
 the securities on public companies.):
(1)Name or code of the new drug under development:
SR-T100 injection.
(2)Purpose: Treatment of malignant ascites in cancer.
(3)Expected R&D stage: Phase I human clinical trial.
(4)Current R&D stage: Preparing to apply to the TFDA for
Phase I human clinical trial (IND).
(5)Next R&D stage:
A.Estimated completion time: Phase I human clinical trial
will officially commence upon approval from the TFDA.
The actual schedule will depend on subsequent review
 progress and clinical execution status.
B.Estimated obligations: None.
(6) Market overview: According to an industry report
released by international market research agency
Credence Research,the global malignant ascites market
size was approximately USD 1.122 billion in 2024 and
is projected to grow to USD 2.269 billion by 2032
(source:Credence Research, ”Malignant
Ascites Market Size, Share, Growth and Forecast 2032”).
(7)Drug development is a lengthy process, requires
significant investment, and does not guarantee success.
Such risks may affect investors. Investors should make
prudent judgments and invest cautiously.